Sitadiet DM 10/100/1000mg Tablet ER 10s

Dapagliflozin + Metformin + Sitagliptin is a powerful oral antidiabetic formulation designed to provide comprehensive glucose control in adults with type 2 diabetes mellitus. It combines three complementary classes of medicines, SGLT2 inhibitor (Dapagliflozin), Biguanide (Metformin), and DPP-4 inhibitor (Sitagliptin), to target multiple pathways involved in elevated blood sugar levels. This makes it particularly beneficial for individuals who have not achieved satisfactory glycaemic control with metformin alone or dual therapies.

Metformin reduces excess glucose production by the liver and improves insulin sensitivity, helping cells use glucose more effectively. Sitagliptin works by increasing incretin hormone levels, thus enhancing insulin release after meals and reducing glucagon secretion. Dapagliflozin promotes the removal of glucose through urine by blocking the SGLT2 transporter in the kidneys, supporting modest weight loss and lowering fasting blood sugar.

Regular use helps reduce HbA1c, fasting glucose, and post-meal spikes, providing round-the-clock control. The combination also offers additional metabolic support, including lowered blood pressure and reduced cardiovascular risk in suitable patients. It should always be taken under medical supervision, especially in people with kidney disease, dehydration risk, or severe gastrointestinal conditions. When combined with healthy eating habits, regular exercise, and weight monitoring, this triple therapy becomes an effective long-term solution for managing type 2 diabetes and preventing complications such as neuropathy, nephropathy, and cardiovascular disease.

• Helps control high blood sugar levels in adults with type 2 diabetes.

• Reduces HbA1c and supports long-term glycaemic control.

• Effective for patients not responding adequately to metformin or dual therapy.

• Helps reduce fasting and post-prandial blood glucose levels.

• Supports weight reduction due to increased urinary glucose excretion.

• May reduce cardiovascular risks in suitable patients.

• Helps prevent diabetes-related complications such as nerve, kidney, and eye damage.

• Comprehensive blood sugar control by addressing three key issues: insulin resistance, excess liver glucose production, and impaired incretin activity.

• Improves both fasting and post-meal glucose levels, supporting stable glycaemic control throughout the day.

• Promotes weight loss, mainly due to dapagliflozin’s glucose-excretion mechanism.

• Helps lower blood pressure, offering added cardiovascular benefits for at-risk or overweight patients.

• Enhances post-meal glucose regulation through sitagliptin’s incretin-based action without causing excess insulin release.

• Reduces the risk of long-term diabetes complications by improving overall metabolic health.

• Increases treatment convenience by combining three medicines into a single formulation, reducing pill burden.

• Increased urination

• Urinary tract infections

• Genital fungal infections

• Nausea, diarrhoea, or stomach discomfort

• Headache or dizziness

• Low blood sugar (especially with other antidiabetic medicines)

• Dehydration or low blood pressure

• Back pain or joint pain

• Metallic taste (due to metformin)

• Rarely: ketoacidosis, kidney problems, or pancreatitis

• Take the medicine exactly as prescribed by your doctor.

• Usually taken once daily with meals to reduce stomach discomfort.

• Swallow the tablet whole with a glass of water; do not crush or chew.

• Maintain adequate hydration during treatment.

• Follow dietary recommendations and monitor blood sugar regularly.

This triple-drug formulation works by addressing three major defects in type 2 diabetes. Metformin reduces hepatic glucose production and increases the body’s sensitivity to insulin, helping cells utilise glucose more effectively. Sitagliptin inhibits the DPP-4 enzyme, increasing incretin hormone levels (GLP-1 and GIP), which stimulate insulin release after meals and suppress excess glucagon.

Dapagliflozin blocks the SGLT2 protein in the kidneys, preventing glucose reabsorption and promoting glucose elimination through urine. This process reduces blood sugar and leads to mild weight loss. Together, these mechanisms control fasting and post-meal glucose levels, reduce insulin resistance, and provide comprehensive glycaemic control with lower risk of hypoglycaemia compared to insulin-based therapies.

• Stay well-hydrated to reduce the risk of dehydration or UTIs.

• Monitor blood glucose regularly, especially when starting therapy.

• Maintain good intimate hygiene to prevent fungal infections.

• Avoid skipping meals to prevent hypoglycaemia.

• Inform your doctor before surgery or hospital admission.

• Store in a cool, dry place away from direct sunlight.

• Keep out of reach of children and pets.

• Do not use tablets past their expiry date.

• Store in original packaging to protect from moisture.

This medicine is generally safe with most foods. However, alcohol significantly increases the risk of lactic acidosis when taken with metformin and should be avoided. Heavy carbohydrate meals may cause post-meal spikes and reduce the drug’s effectiveness. Grapefruit does not interact with this medicine, unlike some other antidiabetics.

Avoid or limit:

• Alcohol

• Sugary or high-glycaemic foods

• Excessive fried or fatty meals

Some medicines may alter the effectiveness of this combination or increase the risk of side effects. Diuretics can worsen dehydration when combined with dapagliflozin. Insulin or sulfonylureas may cause hypoglycaemia when taken together. Certain blood pressure medicines may amplify dizziness or low-BP effects.

Inform your doctor if you are taking:

• Insulin or sulfonylureas

• Diuretics

• Steroids

• Thyroid medicines

• Antiretrovirals

• Anti-epileptics

This combination should be used cautiously in patients with kidney disease, heart failure, dehydration, or recurrent urinary infections. Metformin increases the risk of lactic acidosis in severe kidney or liver impairment. Dapagliflozin may worsen dehydration or blood pressure issues. Sitagliptin may need dose adjustments in renal problems.

Use with caution in:

• Kidney disease

• Liver disease

• Heart failure

• Pancreatitis history

• Frequent UTIs or genital infections

Your doctor will determine the appropriate daily dose based on your blood sugar levels, kidney function, and previous treatment history. The combination is usually taken once daily with meals to minimise stomach upset and ensure optimum glucose control. Do not change the dose without medical supervision.

Taking more than the prescribed dose of Dapagliflozin + Metformin + Sitagliptin can lead to serious side effects, including severe low blood sugar, dehydration, lactic acidosis (a rare but dangerous complication of metformin), or electrolyte imbalance. Seek immediate medical attention or visit the nearest emergency department. Do not attempt to self-treat at home, as timely supportive care and monitoring are essential for safety.

If you forget a dose, take it as soon as you remember. If it is close to the time of your next scheduled dose, skip the missed dose and resume your regular dosing schedule. Do not take two doses together to make up for the missed dose, as this may lead to low blood sugar or side effects. Monitor your glucose levels if you miss a dose and inform your doctor if frequent forgetfulness occurs.